{"id":541058,"date":"2021-09-22T09:04:22","date_gmt":"2021-09-22T13:04:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/"},"modified":"2021-09-22T09:04:22","modified_gmt":"2021-09-22T13:04:22","slug":"amgen-releases-8th-edition-of-biosimilar-trends-report","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/","title":{"rendered":"Amgen Releases 8th Edition of Biosimilar Trends Report"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Report Finds That Competition Created by Biosimilars Delivered $9.8 Billion in Savings Over the Past Five Years to the U.S. Healthcare System, Generating Savings for Patients, Payers and Employers<\/h2>\n<h2 class=\"xn-hedline\">With Both a Strong Innovator Portfolio and a Deep Investment in Biosimilar Products, Amgen has Been a Pioneer in Biotechnology for ~40 Years and Invested Close to $2 Billion Across a Portfolio of 10 Biosimilar Medicines<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">THOUSAND OAKS, Calif.<\/span>, Sept. 22,\u00a02021 \/PRNewswire\/ &#8212;\u00a0Amgen (NASDAQ: AMGN) today released the 8<sup>th<\/sup> edition\u00a0of the\u00a0Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new feature considers how advancements in biosimilars can support the long-term success and sustainability of the U.S. healthcare system.\u00a0To access the full report, visit: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3298183-1&amp;h=2220724814&amp;u=http%3A%2F%2Fwww.amgenbiosimilars.com%2Fcommitment%2Ftrends-report&amp;a=www.amgenbiosimilars.com%2Fcommitment%2Ftrends-report\" rel=\"nofollow noopener\">www.amgenbiosimilars.com\/commitment\/trends-report<\/a>. <\/p>\n<p>To view the multimedia assets associated with this release, please click: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3298183-1&amp;h=2883845834&amp;u=https%3A%2F%2Fwww.multivu.com%2Fplayers%2FEnglish%2F8812854-amgen-8th-edition-biosimilar-trends-report%2F&amp;a=https%3A%2F%2Fwww.multivu.com%2Fplayers%2FEnglish%2F8812854-amgen-8th-edition-biosimilar-trends-report%2F\" rel=\"nofollow noopener\">https:\/\/www.multivu.com\/players\/English\/8812854-amgen-8th-edition-biosimilar-trends-report\/<\/a> \u00a0<\/p>\n<div id=\"prni_dvprnejpg41d7left\" dir=\"ltr\">\n        <img decoding=\"async\" id=\"prnejpg41d7left\" title=\"2021 Biosimilar Trends Report One-pager\" border=\"0\" alt=\"2021 Biosimilar Trends Report One-pager\" align=\"middle\" src=\"https:\/\/www.multivu.com\/players\/English\/8812854-amgen-8th-edition-biosimilar-trends-report\/image\/OnePager_1631816664463-HR.jpg\" \/>\n      <\/div>\n<p>The Report shows that competition created by biosimilars has saved the U.S. healthcare system <span class=\"xn-money\">$9<\/span>.8\u00a0billion over the past five years,<sup>i<\/sup>\u00a0and has the potential to reduce out-of-pocket spending by <span class=\"xn-money\">$238 million<\/span> for patients in the nine biologic drug classes where biosimilars have been approved. According to the Report:<\/p>\n<ul type=\"disc\">\n<li>Biosimilars contribute to competition that drives down healthcare costs by providing significant wholesale acquisition cost (WAC) and average sales price (ASP) discounts at launch, resulting in additional savings over time. <\/li>\n<li>Biosimilars are launching at a price that is generally 15% to 37% lower than the reference product.<sup>ii<\/sup> Furthermore, the ASP is declining for both reference products and biosimilars over time, while the rate of biosimilar uptake is generally increasing over time.<sup>iii,iv<\/sup><\/li>\n<li>Biosimilars have gained substantial share in the majority of therapeutic areas where they have been introduced.<sup>v<\/sup>\u00a0For therapeutic areas with biosimilars launched in the last two years, the average share was 65%.<sup>vi<\/sup><\/li>\n<\/ul>\n<p>This year&#8217;s Report features a new section, Future State of the Marketplace, which outlines how biosimilars can continue to offer more affordable treatment options, drive cost savings through increased competition between biosimilars and with reference biologics, and promote a more resilient U.S. healthcare marketplace. The U.S. marketplace is poised to see further growth in biosimilars approved to date and welcome many new biosimilars in the years to come.<\/p>\n<p>&#8220;As part of Amgen&#8217;s commitment to staying at the forefront of biosimilar education, Amgen is pleased to announce the launch of the 2021 Biosimilar Trends Report,&#8221; said <span class=\"xn-person\">Jennifer Norton<\/span>, vice president, Head of U.S. Value and Access at Amgen. &#8220;The increasing availability and adoption of biosimilars means these treatments are delivering on the fundamental promise of reducing healthcare costs for payers, employers, and patients in <span class=\"xn-location\">the United States<\/span>.&#8221;<\/p>\n<p>The\u00a02021 Biosimilar Trends Report also outlines the four key elements that Amgen believes are necessary for sustaining biosimilars&#8217; growth:<\/p>\n<ul type=\"disc\">\n<li>Implementing scientifically appropriate regulatory standards for the approval, manufacture, and uninterrupted availability of safe and effective biological products, including biosimilars; <\/li>\n<li>Maintaining a marketplace that encourages competition on a level playing field to achieve meaningful savings and long-term stability; <\/li>\n<li>Providing scientifically accurate educational outreach to drive confidence with healthcare providers, patients, payers, and employers; and <\/li>\n<li>Ensuring a foundation of strong intellectual property to encourage innovation and investment.<\/li>\n<\/ul>\n<p>&#8220;The U.S. marketplace with biosimilars is well established and accelerating across key therapeutic areas, creating cost savings, and additional treatment options for physicians and patients,&#8221; said <span class=\"xn-person\">Chad Pettit<\/span>, executive director, Marketing, Global Biosimilars Commercial Lead at Amgen, adding, &#8220;By continuing to advance science-based policies that support competition and enhance confidence from patients, physicians, and other stakeholders, the U.S. can help promote a robust and resilient healthcare system needed for the long term.&#8221; <\/p>\n<p><b>About Amgen Biosimilars<br \/><\/b>Amgen is committed to building upon Amgen&#8217;s experience in the development and manufacturing of innovative human therapeutics to expand Amgen&#8217;s reach to patients with serious illnesses. Biosimilars help to maintain Amgen&#8217;s commitment to connect patients with vital medicines, and Amgen is well positioned to leverage its nearly four decades of experience in biotechnology to create high-quality biosimilars and reliably supply them to patients worldwide.<\/p>\n<p>For more information, visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3298183-1&amp;h=2303834596&amp;u=http%3A%2F%2Fwww.amgenbiosimilars.com%2F&amp;a=www.amgenbiosimilars.com\" rel=\"nofollow noopener\">www.amgenbiosimilars.com<\/a>\u00a0and follow us on <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3298183-1&amp;h=1377736500&amp;u=http%3A%2F%2Fwww.twitter.com%2Famgenbiosim&amp;a=www.twitter.com%2Famgenbiosim\" rel=\"nofollow noopener\">www.twitter.com\/amgenbiosim<\/a>.<\/p>\n<p>\n        <b>About\u00a0Amgen<\/b><br \/>\n        <br \/>Amgen\u00a0is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.<\/p>\n<p>Amgen\u00a0focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people&#8217;s lives. A biotechnology pioneer since 1980,\u00a0Amgen\u00a0has grown to be one of the world&#8217;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.<\/p>\n<p>For more information, visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3298183-1&amp;h=2100306955&amp;u=http%3A%2F%2Fwww.amgen.com%2F&amp;a=www.amgen.com\" rel=\"nofollow noopener\">www.amgen.com<\/a>\u00a0and follow us on\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3298183-1&amp;h=670500660&amp;u=http%3A%2F%2Fwww.twitter.com%2Famgen&amp;a=www.twitter.com%2Famgen\" rel=\"nofollow noopener\">www.twitter.com\/amgen<\/a>.\u00a0\u00a0<\/p>\n<p>CONTACT: Amgen, Thousand Oaks\u00a0<br \/><span class=\"xn-person\">Megan Fox<\/span>, 805-447-1423 (media)<br \/><span class=\"xn-person\">Trish Rowland<\/span>, 805-447-5631(media)\u00a0<br \/><span class=\"xn-person\">Arvind Sood<\/span>, 805-447-1060 (investors)\u00a0<\/p>\n<p>\n        <sup>i<\/sup>\u00a0Data on file, Amgen; Biosimilars Spend Analysis; <span class=\"xn-chron\">July 2021<\/span>.<br \/><sup>ii<\/sup>\u00a0Data on file, Amgen; Product and Biosimilars &#8211; WAC and ASP Price; <span class=\"xn-chron\">July 2021<\/span>.<br \/><sup>iii<\/sup>\u00a0Data on file, Amgen; Product and Biosimilars &#8211; WAC and ASP Price; <span class=\"xn-chron\">July 2021<\/span><br \/><sup>iv<\/sup> Data on file, Amgen; Biosimilars Market Share Trends; <span class=\"xn-chron\">July 2021<\/span><br \/><sup>v<\/sup>\u00a0Data on file, Amgen; Biosimilars Market Share Trends; <span class=\"xn-chron\">July 2021<\/span><br \/><sup>vi<\/sup>\u00a0Data on file, Amgen; Biosimilars Market Share Trends; <span class=\"xn-chron\">July 2021<\/span><\/p>\n<div id=\"prni_dvprnejpgd4f7left\" dir=\"ltr\">\n        <img decoding=\"async\" id=\"prnejpgd4f7left\" title=\"The Promise of Biosimilars Factsheet\" border=\"0\" alt=\"The Promise of Biosimilars Factsheet\" align=\"middle\" src=\"https:\/\/www.multivu.com\/players\/English\/8812854-amgen-8th-edition-biosimilar-trends-report\/image\/Factsheet_1631816664435-HR.jpg\" \/>\n      <\/div>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=AQ14464&amp;sd=2021-09-22\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/amgen-releases-8th-edition-of-biosimilar-trends-report-301382173.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/amgen-releases-8th-edition-of-biosimilar-trends-report-301382173.html<\/a><\/p>\n<p>SOURCE  Amgen<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=AQ14464&amp;Transmission_Id=202109220900PR_NEWS_USPR_____AQ14464&amp;DateId=20210922\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Report Finds That Competition Created by Biosimilars Delivered $9.8 Billion in Savings Over the Past Five Years to the U.S. Healthcare System, Generating Savings for Patients, Payers and Employers With Both a Strong Innovator Portfolio and a Deep Investment in Biosimilar Products, Amgen has Been a Pioneer in Biotechnology for ~40 Years and Invested Close to $2 Billion Across a Portfolio of 10 Biosimilar Medicines PR Newswire THOUSAND OAKS, Calif., Sept. 22,\u00a02021 \/PRNewswire\/ &#8212;\u00a0Amgen (NASDAQ: AMGN) today released the 8th edition\u00a0of the\u00a0Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new feature considers how advancements in biosimilars can support the long-term success and sustainability of the U.S. healthcare &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Amgen Releases 8th Edition of Biosimilar Trends Report&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-541058","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amgen Releases 8th Edition of Biosimilar Trends Report - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen Releases 8th Edition of Biosimilar Trends Report - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Report Finds That Competition Created by Biosimilars Delivered $9.8 Billion in Savings Over the Past Five Years to the U.S. Healthcare System, Generating Savings for Patients, Payers and Employers With Both a Strong Innovator Portfolio and a Deep Investment in Biosimilar Products, Amgen has Been a Pioneer in Biotechnology for ~40 Years and Invested Close to $2 Billion Across a Portfolio of 10 Biosimilar Medicines PR Newswire THOUSAND OAKS, Calif., Sept. 22,\u00a02021 \/PRNewswire\/ &#8212;\u00a0Amgen (NASDAQ: AMGN) today released the 8th edition\u00a0of the\u00a0Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new feature considers how advancements in biosimilars can support the long-term success and sustainability of the U.S. healthcare &hellip; Continue reading &quot;Amgen Releases 8th Edition of Biosimilar Trends Report&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-22T13:04:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.multivu.com\/players\/English\/8812854-amgen-8th-edition-biosimilar-trends-report\/image\/OnePager_1631816664463-HR.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Amgen Releases 8th Edition of Biosimilar Trends Report\",\"datePublished\":\"2021-09-22T13:04:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/\"},\"wordCount\":917,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.multivu.com\\\/players\\\/English\\\/8812854-amgen-8th-edition-biosimilar-trends-report\\\/image\\\/OnePager_1631816664463-HR.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/\",\"name\":\"Amgen Releases 8th Edition of Biosimilar Trends Report - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.multivu.com\\\/players\\\/English\\\/8812854-amgen-8th-edition-biosimilar-trends-report\\\/image\\\/OnePager_1631816664463-HR.jpg\",\"datePublished\":\"2021-09-22T13:04:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.multivu.com\\\/players\\\/English\\\/8812854-amgen-8th-edition-biosimilar-trends-report\\\/image\\\/OnePager_1631816664463-HR.jpg\",\"contentUrl\":\"https:\\\/\\\/www.multivu.com\\\/players\\\/English\\\/8812854-amgen-8th-edition-biosimilar-trends-report\\\/image\\\/OnePager_1631816664463-HR.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-releases-8th-edition-of-biosimilar-trends-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen Releases 8th Edition of Biosimilar Trends Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amgen Releases 8th Edition of Biosimilar Trends Report - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/","og_locale":"en_US","og_type":"article","og_title":"Amgen Releases 8th Edition of Biosimilar Trends Report - Market Newsdesk","og_description":"Report Finds That Competition Created by Biosimilars Delivered $9.8 Billion in Savings Over the Past Five Years to the U.S. Healthcare System, Generating Savings for Patients, Payers and Employers With Both a Strong Innovator Portfolio and a Deep Investment in Biosimilar Products, Amgen has Been a Pioneer in Biotechnology for ~40 Years and Invested Close to $2 Billion Across a Portfolio of 10 Biosimilar Medicines PR Newswire THOUSAND OAKS, Calif., Sept. 22,\u00a02021 \/PRNewswire\/ &#8212;\u00a0Amgen (NASDAQ: AMGN) today released the 8th edition\u00a0of the\u00a0Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new feature considers how advancements in biosimilars can support the long-term success and sustainability of the U.S. healthcare &hellip; Continue reading \"Amgen Releases 8th Edition of Biosimilar Trends Report\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-22T13:04:22+00:00","og_image":[{"url":"https:\/\/www.multivu.com\/players\/English\/8812854-amgen-8th-edition-biosimilar-trends-report\/image\/OnePager_1631816664463-HR.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Amgen Releases 8th Edition of Biosimilar Trends Report","datePublished":"2021-09-22T13:04:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/"},"wordCount":917,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.multivu.com\/players\/English\/8812854-amgen-8th-edition-biosimilar-trends-report\/image\/OnePager_1631816664463-HR.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/","name":"Amgen Releases 8th Edition of Biosimilar Trends Report - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.multivu.com\/players\/English\/8812854-amgen-8th-edition-biosimilar-trends-report\/image\/OnePager_1631816664463-HR.jpg","datePublished":"2021-09-22T13:04:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/#primaryimage","url":"https:\/\/www.multivu.com\/players\/English\/8812854-amgen-8th-edition-biosimilar-trends-report\/image\/OnePager_1631816664463-HR.jpg","contentUrl":"https:\/\/www.multivu.com\/players\/English\/8812854-amgen-8th-edition-biosimilar-trends-report\/image\/OnePager_1631816664463-HR.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-releases-8th-edition-of-biosimilar-trends-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Amgen Releases 8th Edition of Biosimilar Trends Report"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/541058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=541058"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/541058\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=541058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=541058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=541058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}